FDMT
4D Molecular Therapeutics, Inc.
Key Financials
Operating Income
$-159547000
↑ 15.1%
Revenue
$85.2M
↑ 230194.6%
Net Income
$-140109000
↑ 12.9%
Total Assets
$566.7M
↑ 1.1%
EPS (Diluted)
$-2.42
↑ 18.8%
Shareholders' Equity
$505.7M
↓ 1.0%
Cash & Equivalents
$60.2M
↓ 59.7%
Total Liabilities
$61.0M
↑ 22.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 4/7/2026 | View on SEC |
| 8-K | 3/30/2026 | View on SEC |
| 4 | 3/27/2026 | View on SEC |
| 4 | 3/27/2026 | View on SEC |
| 4 | 3/27/2026 | View on SEC |
| SCHEDULE 13G/A | 3/26/2026 | View on SEC |
| 4 | 3/24/2026 | View on SEC |
| S-8 | 3/18/2026 | View on SEC |
| 10-K | 3/18/2026 | View on SEC |
| 8-K | 3/18/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | FDMT |
| Company Name | 4D Molecular Therapeutics, Inc. |
| CIK | 1650648 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 5105052680 |